
NYSE:BDX
This summary was created by AI, based on 2 opinions in the last 12 months.
Becton Dickinson (BDX) has undergone significant structural changes following the spin-off of its life sciences business and subsequent merger with Waters Corp, positioning itself as a pure-play medical technology company. Management has adjusted their earnings expectations for 2026 from $15 EPS down to $12.50, indicating a shift in focus towards higher-growth, higher-margin sectors. The operating margin expectations have also seen an improvement, rising from 21% to 25%. While the stock appears reasonably priced at 14x earnings, the changes have introduced a level of risk that warrants a cautious approach. Analysts have set a price target of $200, but macroeconomic factors affecting the hospital segment remain a concern for investors looking for stability.
(A Top Pick Aug 29/18, Up 18%) They do healthcare--hospitals, clinics--as an end-to-end service provider. They give hospital admin the software and provide all the products you'd need, like catheters or surgical equipment. Really they have no competition. Their customers stay loyal. They made a recent acquisition that gives them more international exposure. It doesn't have as much regulatory risk as other healthcare or pharma companies.
It was a top pick for him in the past recently acquired CR Bald. A one stop shop for hospitals and clinics for all one time use medical devices (needles, etc.). Full service company from sales to programming to reordering, etc. now a gigantic company. Very good earnings. Very good guidance. They are going to benefit from tax reform. Big tail winds in healthcare. The biggest risk in healthcare is what Amazon is going to do. But not a lot of competition on the space. Just the US government spends 1.3 trillion dollars a year in health care.
Manufactures syringes and other medical devices. Just completed a big merger. The merger of 2 strong free cash flow growing companies has made them a powerhouse, and the stock has taken off after the announcement of the acquisition. Expectation is 10% free cash flow growth, and as a result, 10% dividend growth over time.